Showing 3971-3980 of 7601 results for "".
- Obagi Launches SKINCLUSION Initiative to Celebrate Diversity with Brand Ambassador Priyanka Chopra Jonashttps://practicaldermatology.com/news/obagi-launches-skinclusion-initiative-to-celebrate-diversity-with-brand-ambassador-and-priyanka-chopra-jonas/2460026/Obagi kicked off its SKINCLUSION initiative, designed to elevate the global dialogue about diversity and how we can all make conscious choices to see the beauty in all of our differences, with an event in New York City introducing Priyanka Chopra Jonas as its SKINCLUSION ambassador. Priyanka, an
- Sensus Healthcare Awarded Brachytherapy Products Agreement with Premierhttps://practicaldermatology.com/news/sensus-healthcare-awarded-brachytherapy-products-agreement-with-premier/2460025/Sensus Healthcare, Inc.has been awarded a group purchasing agreement for Brachytherapy Products with Premier. Effective August 1, 2019, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Sensus’ SRT-100
- Abeona Therapeutics to Present EB-101 Data at Society for Investigative Dermatology Annual Meetinghttps://practicaldermatology.com/news/abeona-therapeutics-to-present-eb-101-data-at-society-for-investigative-dermatology-annual-meeting/2460024/Long-term follow up data from a completed Phase 1/2 study evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) will be presented at the 77th Annual Meeting of the Society for Investigative Dermatology (SID) in Chicago. The data will be presented by Stanfor
- Aesthetic Innovations Summit Coming to New Orleanshttps://practicaldermatology.com/news/aesthetic-innovations-summit-coming-to-new-orleans/2460022/Coming off an impressive inaugural meeting in 2018, the second annual Aesthetics Innovation Summit will unite over 300 of the most influential corporate, capital, and clinical leaders in New Orleans to collaborate on the development and adoption of new aesthetic treatments and technologies.
- AAD: Half of Americans Aren't Protecting Themselves from the Sunhttps://practicaldermatology.com/news/aad-half-of-americans-arent-protecting-themselves-from-the-sun/2460018/Most Americans aren’t using sun protection as often as they should be —increasing their risk for skin cancer, including melanoma. In fact, just half of Americans always or almost always protect themselves from the sun when they’re outside, according to a new survey by
- Crown Labs Adds to Portfolio with Acquisition of Keri from GSKhttps://practicaldermatology.com/news/crown-labs-adds-to-portfolio-with-acquisition-of-keri-from-gsk/2460017/Crown Laboratories, Inc. acquired the North American rights for Keri from GlaxoSmithKline (GSK). The acquisition of Keri from GSK marks the sixth product from GSK that Crown has acquired in the past five months. “Acqui
- ISHRS Awareness Campaign Takes on Black Market Hair Restoration Clinicshttps://practicaldermatology.com/news/ishrs-awareness-campaign-takes-on-black-market-hair-restoration-clinics/2460016/The International Society of Hair Restoration Surgery (ISHRS) is launching a new public awareness campaign to help patients recognize “black market pirate” hair restoration clinics and misleading advertising claims. Social media engagement will be the cornerstone of the new
- Study Highlights Adverse Events Associated with Energy-Based Vaginal Rejuvenationhttps://practicaldermatology.com/news/study-highlights-adverse-events-associated-with-energy-based-vaginal-rejuvenation/2460010/Concerns from the federal Food and Drug Administration (FDA) sired the first assessment of adverse events related to device-based procedures marketed for ‘vaginal rejuvenation,’ and the new analysis of the Manufacturer and User Facility Device Experience (MAUDE) database identified a
- FDA Approves Ortho Dermatologics' Duobrii for Treatment of Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-ortho-dermatologics-duobrii-for-treatment-of-plaque-psoriasis/2460009/The FDA has approved Ortho Dermatologics' New Drug Application for Duobrii (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, indicated for the topical treatment of plaque psoriasis in adults. Duobrii is the only topical lotion that contains a unique combination of halobetasol prop
- Ovation Science Appoints Medical Dermatology Advisory Boardhttps://practicaldermatology.com/news/ovation-science-appoints-medical-dermatology-advisory-board/2460008/Ovation Science, Inc. has entered into an exclusive agreement with Skincareguide.com Ltd., to act as the Company's Medical Dermatology Advisory Board for cannabis formulated products. The objective of the Medical Dermatology Advisory Board is to provide guidance, along with clinical, scientif